Cellecta, Inc. Receives Phase II NIH SBIR Grant to Develop Advanced CRISPR/Cas9 Genome-Wide sgRNA Library Screening Platform

Development of a high-performance tool set for human and mouse genetic screens to enable enhanced drug discovery underway NEWS PROVIDED BY Cellecta, Inc. 26 Jan, 2017, 08:40 ET SHARE THIS ARTICLE MOUNTAIN VIEW, Calif., Jan. 26, 2017 /PRNewswire/ — Cellecta, Inc. today announced the receipt of Phase II SBIR grant funds from the National Institute of... Read more

Takara Bio USA Holdings, Inc. completes acquisition of Rubicon Genomics, Inc.

Takara Bio USA Holdings, Inc. completes acquisition of Rubicon Genomics, Inc. Mountain View, CA—January 18, 2017—Takara Bio USA Holdings, Inc. (“TBUSH”) announced that it has completed the acquisition of Rubicon Genomics, Inc. (“Rubicon”), Rubicon has become a wholly-owned subsidiary of TBUSH as of January 17, 2017 (US local time). Under the merger agreement executed with Rubicon,... Read more

Congenica Expands in North America with Strategic Appointment

Congenica Expands in North America with Strategic Appointment Shikha O’Brien, Chief Business Officer Genomics Analysis Leader Appoints Dr Shikha O’Brien as Chief Business Officer 16th January 2017, Cambridge UK Congenica, a world leading developer of genome analysis and interpretation technologies, expands its operations in the US with the announcement that it has recruited Dr Shikha... Read more

Bio-Rad To Acquire RainDance Technologies and Droplet Intellectual Property

HERCULES, Calif. — January 16, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced today that it has entered into a definitive agreement to purchase RainDance Technologies, Inc. The terms of the acquisition were not disclosed. Bio-Rad expects the transaction to close during... Read more

Novogene Agrees to Buy Ten PacBio Sequel Systems for DNA Sequencing Services

MENLO PARK, Calif., and BEIJING, Jan. 16, 2017 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB) and Novogene Corporation, a leading provider of genomic and bioinformatic services, today announced that Novogene has agreed to purchase 10 Sequel™ Systems for whole genome sequencing, Iso-Seq™ annotation and targeted sequencing services.PacBio’s sequencing systems are based on its... Read more

More Than 115 Presentations and Posters Feature PacBio SMRT Sequencing to Decipher Complex Plant and Animal Genomes at Annual PAG Conference

MENLO PARK, Calif., Jan. 12, 2017 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB) today announced that its Single Molecule, Real-Time (SMRT®) Sequencing technology will be featured in at least 57 podium presentations and 60 posters at the International Plant & Animal Genome (PAG) XXV Conference  taking place January 14-18 in San Diego, California.  From specialty beverage... Read more

Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases

SAN DIEGO and HERCULES, Calif. — January 9, 2017 — Illumina, Inc. (NASDAQ: ILMN) and Bio‑Rad Laboratories, Inc. (NYSE: BIO)(NYSE: BIOb) today announced the launch of the Illumina® Bio-Rad® Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference, San Francisco. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers... Read more

Pacific Biosciences Improves Key Applications on the Sequel System with New Chemistry and Software Release

Monday, January 9, 2017 MENLO PARK, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB) today announced a new version of chemistry (V2) and software (V4) for the Sequel™ System. The new release improves the system’s ability to support important applications such as structural variant detection and targeted sequencing—including metagenomics, minor... Read more

UPDATE — Pacific Biosciences Improves Key Applications on the Sequel System with New Chemistry and Software Release

MENLO PARK, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB) today announced a new version of chemistry (V2) and software (V4) for the Sequel™ System. The new release improves the system’s ability to support important applications such as structural variant detection and targeted sequencing—including metagenomics, minor variant detection and isoform... Read more